{‘She lacks no experience’: this US scientific field prepares for Tracy Beth Høeg’s tenure at the Food and Drug Administration.

While the United States continues making sweeping revisions to its vaccination guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 shots in the pandemic and has zeroed in on potential deaths following COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Program

Agency leaders had intended to unveil major revisions to the childhood vaccine schedule in December, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US at odds with many the global community with no evidence for benefit. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to speak at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

To date statements, she has kept her attention on vaccines – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no obvious background in medication creation, regulation or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a large organization. She is not an expert in industry regulation.”

Former directors of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the kind of background that former directors who ran CBER have had.”

This division has an vast range of responsibilities at the agency, the former commissioner pointed out.

“The public just zeroes in on the new drug program, but the generic drug division approves a multitude of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and all of those need to be managed,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a major management aspect to the role, which supervises in excess of 5,000 employees. “It is a enormous administrative position, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Programs

Regarding concerns about Dr. Høeg's qualifications and whether this appointment signifies more teamwork among regulatory chiefs on vaccines, a press secretary said that the “inquiries stem from inaccurate premises”.

“Her resume is consistent with the responsibilities of her position,” the representative said, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious one-day drug-approval program that allegedly worried her predecessors. “By what process are these therapies being chosen for this voucher program? Who takes the calls?” Howard asked. “There is a lot of secrecy going on at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of pharmaceuticals, with the exception of shots.”

Established Track Record on Vaccines

Concerning immunizations, Høeg has a more established, if concerning, past, Howard said. She authored a research paper using unverified volunteer-provided data to determine the rate of myocarditis after COVID-19 immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the current federal leadership included altering guidelines for recently developed shots and ending “optional” vaccines, she stated following the vote on a podcast. At the FDA, Dr. Høeg has according to sources proposed barring adolescent males from receiving COVID-19 vaccinations.

“She’s an thorough true believer who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a very disingenuous, untruthful fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|